Further, 70% of the predicted neuroendocrine neoplasms, a favorable CUP subgroup with specific treatments and good outcomes, were found to express the classical neuroendocrine markers, including Syn, CgA, and CD56. The gene discussed is NCAM1; the disease is neuroendocrine neoplasm.